A combination of GO-203 and the DNMT1 inhibitor decitabine can effectively decrease DNMT1 levels and the survival rate of AML cells considering that MUC1-C is an attractive target for the epigenetic reprogramming of AML cells, which can significantly reduce gene promoter-specific DNA methylation and further inhibit the expression of tumor suppressor genes, such as breast-cancer susceptibility gene 1 (BRCA1), cadherin 1 (CDH1), and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) 97. Here, DNMT1 is linked to acute myeloid leukemia.